K-Glim-M 1mg Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose utilization. The combination of these agents provides complementary mechanisms of action, resulting in more effective blood glucose regulation than either agent alone. K-Glim-M 1mg Tablet PR is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy. It is particularly beneficial in patients with insulin resistance and diminished beta-cell function. The extended-release formulation allows for once-daily dosing, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoglycemia. Regular monitoring of blood glucose, renal function, and HbA1c levels is recommended to optimize therapy and minimize adverse effects. K-Glim-M 1mg Tablet PR should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.